IPO Alert: Tatva Chintan
Pharma Chem opens on 16 July 2021
The IPO season
continues, especially with specialty chemicals manufacturers making a beeline
to list on the stock markets. Tatva Chintan Pharma Chem will be the fifth
specialty chemical company to hit the markets in the last 12 months. We bring
you all the details about this IPO, which is open for subscription from 16 to
20 July.
Key details
·
IPO size: ₹500 crore
·
Fresh issue: ₹225 crore
·
Price band: ₹1073–₹1083 per share
·
Lot size: 13 shares
·
Cost per lot: ₹14,079
·
Issue opens: 16 July 2021
·
Issue closes: 20 July 2021
·
Basis of allotment date: 26 July
2021
·
Initiation of refunds: 27 July 2021
·
Credit of shares to demat account: 28
July 2021
·
Expected listing date: 29 July 2021
About Tatva
Chintan Pharma Chem
Established in
1996, Gujarat-based Tatva Chintan Pharma Chem is a specialty chemicals
manufacturer with a diverse portfolio of 154 products. The company makes
structure directing agents (SDAs), phase transfer catalysts (PTCs),
pharmaceutical and agrochemical intermediates. These chemicals are used in
various sectors including automotive, petroleum, dyes and pigments, paints and
coatings and personal care.
Tatva Chintan
Pharma is an export-oriented company, with 70% of its total revenue coming from
overseas markets, including the US, China and South Africa.
The company has
reported strong growth over the past three years. Its revenue and net profit
have surged at a CAGR of 20.5% and 59.5%, respectively, during FY19–21.
About the issue
The IPO size is
₹500 crore, with a fresh issue of ₹225 crore, which will be used by the company
for capex expansion of the Dahej manufacturing facility and upgradation at the
R&D facility in Vadodara. The remaining ₹275 crore is an offer for
sale.
IPO allocation quota
|
QIB
|
NIB
|
Retail
|
|
50%
|
15%
|
35%
|
To know more
about the IPO, read its red herring prospectus here. The issue
opens on 16 July 2021 and you can subscribe to Tatva Chintan Pharma
Chem with Upstox here. Meanwhile,
we’ll keep you posted on all the updates about this IPO and the public issues
that follow, so stay tuned!
